| Name | Title | Contact Details |
|---|---|---|
Tony Meehan |
Chief Financial Officer | Profile |
Timothy Niedrist |
Associate Director of Financial Operations | Profile |
Ajit Roy |
Senior Director of Clinical R&D | Profile |
Helen Libman |
Senior Director, Analytical R&D | Profile |
AA Medical Store improves healthcare around the world by supplying refurbished state-of the-art surgical devices at the best price, with the best warranty, and unmatched service and support.
Hillsides is a premier provider dedicated to improving the overall well-being and functioning of vulnerable children, youth, and their families.
Bayless Healthcare offers a progressive approach to Integrated Healthcare in the Phoenix area. Services include primary care, behavioral health & counseling services & wellness programs.
Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.